{"id":15574,"date":"2025-08-21T09:20:37","date_gmt":"2025-08-21T07:20:37","guid":{"rendered":"https:\/\/eestiarst.ee\/?p=15574"},"modified":"2025-08-21T09:20:37","modified_gmt":"2025-08-21T07:20:37","slug":"car-t-cell-therapy-as-a-step-towards-personalised-medicine-and-more-promising-cancer-treatment","status":"publish","type":"post","link":"https:\/\/eestiarst.ee\/en\/car-t-cell-therapy-as-a-step-towards-personalised-medicine-and-more-promising-cancer-treatment\/","title":{"rendered":"CAR T-cell therapy as a step towards personalised medicine and more promising cancer treatment"},"content":{"rendered":"<p>Chimeric antigen receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy in which a patient&#8217;s T-cells are genetically engineered with the help of viral vectors to express chimeric antigen receptors (CARs), enabling them to recognize and eliminate cancer cells. CAR-T therapy has demonstrated significant efficacy in haematological malignancies like B-cell lymphoma, B-cell acute lymphoblastic leukaemia, and multiple myeloma. This therapy was first approved by the FDA in 2017, and by the EMA in 2018.<br \/>\nCommon adverse effects associated with CAR-T therapy mostly include acute conditions like cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy (CRES), making early detection crucial. This therapy\u2019s limitations consist of limited efficacy in solid tumours, its high cost of manufacturing, and the complexity of T-cell genetic modification. Despite these obstacles, CAR-T therapy is often used as a last resort for patients with relapsed\/ refractory hematologic malignancies for whom previous treatment has failed.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chimeric antigen receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy in which a patient&#8217;s T-cells are genetically engineered with the help of viral vectors to express chimeric antigen receptors (CARs), enabling them to recognize and eliminate cancer cells. CAR-T therapy has demonstrated significant efficacy in haematological malignancies like B-cell lymphoma, B-cell acute lymphoblastic &#8230;<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[1538],"class_list":["post-15574","post","type-post","status-publish","format-standard","hentry","category-articles","tag-review","authors-rand-et-al"],"acf":[],"_links":{"self":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/15574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/comments?post=15574"}],"version-history":[{"count":1,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/15574\/revisions"}],"predecessor-version":[{"id":15575,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/15574\/revisions\/15575"}],"wp:attachment":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/media?parent=15574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/categories?post=15574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/tags?post=15574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}